Skip to main content
Springer Nature Link
Log in

Are basal D-serine plasma levels a predictive biomarker for the rapid antidepressant effects of ketamineand ketamine metabolites?

  • Letter to the Editor
  • Published:
Psychopharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
€32.70 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Singapore)

Instant access to the full article PDF.

Institutional subscriptions

References

  • Dwyer JM, Duman RS (2013) Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biol Psychiatry 73:1189–1198

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Leung LY, Baillie TA (1986) Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. J Med Chem 29:2396–2399

    Article  PubMed  CAS  Google Scholar 

  • Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L, Rosenberg A, Tran T, Xiao Y, Zarate CA Jr, Wainer IW (2013) Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors. Eur J Pharmacol 698:228–234

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Moaddel R, Luckenbaugh DA, Xie Y, Villasenor A, Brutsche NE, Machado-Vieira R, Ramamoorthy A, Lorenzo MP, Carcia A, Bernier M, Torjman MC, Barbas C, Zarate CA, Wainer JW (2014) d-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with major depressive disorder. Psychopharmacology. doi:10.1007/s00231-014-3669-0

  • Paul RK, Singh NS, Khadeer M, Moaddel R, Sanghvi M, Green CE, O’Loughlin K, Torjman MC, Bernier M, Wainer IW (2014) (R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin (mTOR) function. Anesthesiology 121:149–159

    Article  PubMed  CAS  Google Scholar 

  • Singh NS, Paul RK, Ramamoorthy A, Torjman MC, Moaddel R, Bernier M, Wainer IW (2013) Nicotinic acetylcholine receptor antagonists alter the function and expression of serine racemase in PC-12 and 1321N1 cells. Cell Signal 25:2634–2645

    Article  PubMed  CAS  Google Scholar 

  • Zhang JC, Li SX, Hashimoto K (2014) R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 116:137–141

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The work cited in this response was supported by funds from the Intramural Research Program of the National Institute on Aging of the US National Institutes of Health.

Conflict of interest

Irving W. Wainer is listed as the lead inventor on a patent application for the use of (2S,6S)-hydroxynorketamine and other ketamine metabolites in the treatment of depression and neuropathic pain. Dr. Wainer has assigned his rights in the patent to the U.S. Government but will receive a percentage of any royalties that may be received by the government.

Author information

Authors and Affiliations

  1. Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA

    Irving W. Wainer

  2. Mitchell Woods Pharmaceuticals, Four Corporate Drive, Suite 287, Shelton, CT, 06484, USA

    Irving W. Wainer

Authors
  1. Irving W. Wainer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Irving W. Wainer.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wainer, I.W. Are basal D-serine plasma levels a predictive biomarker for the rapid antidepressant effects of ketamineand ketamine metabolites?. Psychopharmacology 231, 4083–4084 (2014). https://doi.org/10.1007/s00213-014-3736-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-014-3736-6

Keywords

Search

Navigation